Cognition Therapeutics Ownership
| CGTX Stock | USD 0.45 0.02 4.65% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 40.4 M | Current Value 41.5 M | Avarage Shares Outstanding 27.1 M | Quarterly Volatility 7.2 M |
Cognition |
Cognition Stock Ownership Analysis
About 18.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cognition Therapeutics recorded a loss per share of 0.86. The entity had not issued any dividends in recent years. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York. Cognition Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. For more info on Cognition Therapeutics please contact Lisa Ricciardi at 412 481 2210 or go to https://www.cogrx.com.Besides selling stocks to institutional investors, Cognition Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cognition Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cognition Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cognition Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of Cognition Therapeutics are currently held by insiders. Unlike Cognition Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cognition Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cognition Therapeutics' insider trades
Cognition Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cognition Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cognition Therapeutics backward and forwards among themselves. Cognition Therapeutics' institutional investor refers to the entity that pools money to purchase Cognition Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-12-31 | 91.1 K | Commonwealth Equity Services Inc | 2024-12-31 | 90.7 K | Virtu Financial Llc | 2024-12-31 | 80.2 K | Two Sigma Investments Llc | 2024-12-31 | 53.7 K | Fca Corp | 2024-12-31 | 51.5 K | Circle Wealth Management, Llc | 2024-12-31 | 48.8 K | Northern Trust Corp | 2024-12-31 | 47.5 K | Castle Wealth Management Llc | 2024-12-31 | 43.4 K | Ubs Group Ag | 2024-12-31 | 41.1 K | Bios Capital Management, Lp | 2024-12-31 | 6 M | Vanguard Group Inc | 2024-12-31 | 1.2 M |
Cognition Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cognition Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cognition Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cognition Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cognition Therapeutics Outstanding Bonds
Cognition Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cognition Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cognition bonds can be classified according to their maturity, which is the date when Cognition Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.